ConCallIQ
Go Pro
Home › Gland Pharma › Margin Trend

Gland Pharma Margin Trend — Quarter by Quarter

Gland Pharma's EBITDA margin moved from 24.0% in Q1 FY26 to 30.0% in Q4 FY26 across 4 quarters. Management commentary below explains the cost and pricing drivers mentioned on calls.

EBITDA Margin by Quarter

QuarterEBITDA Margin (%)YoY Change
Q4 FY2630.0%+500 bps
Q3 FY2626.0%—
Q2 FY2621.0%—
Q1 FY2624.0%+500 bps

What management said about ebitda margin

G

Q4 FY26 · Base business EBITDA margin of 35% for FY27

Base business EBITDA margin expected to be around 35% for FY27, supported by operating leverage and cost efficiencies.

G

Q4 FY26 · SenXi mid-teen EBITDA margin in medium term

SenXi targets mid-teen EBITDA margin in the medium term, with FY27 expected to reach high single-digit EBITDA margin.

G

Q2 FY26 · Senexi EBITDA breakeven in Q3 FY26

Senexi is expected to achieve EBITDA breakeven in Q3 FY26, supported by €50M quarterly revenue target.

G

Q1 FY26 · Synergia positive EBITDA by Q3 FY26

Synergia is committed to delivering positive EBITDA in Q3 FY26, after a lower Q2 due to summer shutdown.